Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10809	Companies
234058	Keywords
162793	Articles
125046	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 2 years ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA

Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study
BRIEF

published on 07/01/2024 at 07:05, 2 years 1 month ago

Biophytis Presents Promising Phase 2-3 COVA Study Results on Severe Covid-19 at WCID in Paris

Biophytis COVID-19 Clinical Trials COVA Study Infectious Diseases
PRESS RELEASE

published on 07/01/2024 at 07:00, 2 years 1 month ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presents positive results from Phase 2-3 COVA study for severe Covid-19 at WCID Paris. Bio101 shows significant efficacy and safety in reducing risk of respiratory failure and death

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study Respiratory Failure
REGULATED PRESS RELEASE

published on 07/01/2024 at 07:00, 2 years 1 month ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presented positive results of its Phase 2-3 COVA study for severe Covid-19 at WCID in Paris, showing reduction in respiratory failure and death rates

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study
BRIEF

published on 06/25/2024 at 23:05, 2 years 1 month ago

Biophytis Approves All Resolutions at General Meeting

Shareholders Biophytis General Meeting Resolutions
REGULATED PRESS RELEASE

published on 06/25/2024 at 23:00, 2 years 1 month ago

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
Biophytis SA announces the approval of all resolutions at the combined general meeting held on June 24, 2024, with significant shareholder participation

Shareholders General Meeting Resolutions Approval Biophytis SA
BRIEF

published on 06/20/2024 at 07:05, 2 years 1 month ago

Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at Up to €108 Million

Biophytis Pharmaceuticals Latin America BIO101 Blanver
PRESS RELEASE

published on 06/20/2024 at 07:00, 2 years 1 month ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 million. Agreement includes upfront and milestones payments, double-digit royalties, and collaboration on manufacturing and clinical development

Biophytis Latin America Exclusive Rights Blanver Pharmaceutical Deal
REGULATED PRESS RELEASE

published on 06/20/2024 at 07:00, 2 years 1 month ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million. Collaboration for commercialization and clinical development announced

Biophytis Latin America BIO101 Exclusive Rights Blanver
BRIEF

published on 06/20/2024 at 01:15, 2 years 1 month ago

Biophytis extends its contract with Atlas to finance its clinical activities

Biophytis Biotechnology Convertible Bonds Funding Atlas

Accesswire

Published on 08/06/2026 at 15:00, 1 hour 47 minutes ago

Norsemont Strategically Expands Choquelimpie Land Package To 9,048 Hectares
Published on 08/06/2026 at 14:30, 2 hours 17 minutes ago

Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook
Published on 08/06/2026 at 14:30, 2 hours 17 minutes ago

NV Gold Announces Expansion of Holdings and Drill Program at the Slumber Gold Project in Nevada
Published on 08/06/2026 at 14:30, 2 hours 17 minutes ago

AIAI Holdings' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare
Published on 08/06/2026 at 14:00, 2 hours 47 minutes ago

Adcore to Publish Second Quarter 2026 Results on August 13, 2026

View all ACCESSWIRE

EQS Group

Published on 08/06/2026 at 16:15, 32 minutes ago

Monotype and Kittl Expand Partnership To Bring Brand Typography Directly Into Creative Workflows
Published on 08/06/2026 at 15:20, 1 hour 27 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 08/06/2026 at 15:19, 1 hour 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 08/06/2026 at 15:19, 1 hour 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/06/2026 at 15:18, 1 hour 29 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited

Les Echos

Published on 08/06/2026 at 08:00, 8 hours 47 minutes ago

EURAZEO ENTERS INTO EXCLUSIVE DISCUSSIONS WITH PARTNERS GROUP REGARDING THE CONTEMPLATED SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT
Published on 08/05/2026 at 18:00, 22 hours 47 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of July 31, 2026
Published on 08/05/2026 at 17:49, 22 hours 57 minutes ago

Mersen: Number of shares and voting rights as of July 31, 2026
Published on 08/05/2026 at 17:45, 23 hours 2 minutes ago

Information concerning the total number of voting rights and shares 2026 07 31
Published on 08/05/2026 at 17:45, 23 hours 2 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE